Dear Dr. Kuntz:

Please refer to your Supplemental New Drug Applications (sNDA) dated May 10, 2013, received May 13, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Kaletra (lopinavir/ritonavir) 200 mg/50 mg and 100 mg/25 mg tablets and Kaletra (lopinavir/ritonavir) 80 mg/20 mg oral solution.

We acknowledge receipt of your amendments dated October 1 and 11, 2013.

These Prior Approval supplemental new drug applications propose the following changes to the labeling:

1. To update ADVERSE DRUG REACTIONS section of labeling with the conversion of adverse drug reactions for adults who participated in Phase 2 – 4 clinical trials from COSTART to MeDRA terminology
2. To update CLINICAL PHARMACOLOGY section of labeling with the mechanism of action of ritonavir.
3. To update “Common side effects of KALETRA”, section of the Medication Guide to include information related to increased levels of fats in blood

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA
automated drug registration and listing system (eLIST), as described at
of labeling must be identical to the enclosed labeling (text for the package insert and Medication
Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE)
supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled
“SPL Standard for Content of Labeling Technical Qs and As at
CM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes
for this NDA, including CBE supplements for which FDA has not yet issued an action letter,
with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the
changes approved in this supplemental application, as well as annual reportable changes and
annotate each change. To facilitate review of your submission, provide a highlighted or marked-
up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy
should provide appropriate annotations, including supplement number(s) and annual report
date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new
active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of
administration are required to contain an assessment of the safety and effectiveness of the
product for the claimed indication(s) in pediatric patients unless this requirement is waived,
defered, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional
labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory
comments, (2) the proposed materials in draft or mock-up form with annotated references, and
(3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266
You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Linda C. Onaga, MPH, Regulatory Project Manager, at (301) 796-0759 or the Division mainline at (301) 796-1500.

Sincerely,

{See appended electronic signature page}

Kendall Marcus, MD
Deputy Director of Safety
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

KENDALL A MARCUS
11/07/2013